The Asia Pacific pain management drugs market is growing at the most rapid pace of 4.73% CAGR during the forecasting period 2019-2027. China, India, Japan, Australia, South Korea and the collective countries from the Rest of Asia Pacific are considered for the regional market study. The steady increase in healthcare expenditure is mainly driving the pain management market growth.
There has been a surge in the frequency of chronic diseases like diabetic neuropathy and osteoarthritis that has been propelling the market growth. The government initiative to improve the accessibility of pain medication in developing countries such as China and India can be responsible for the market growth in the upcoming years. Also, there has been an increase in R&D investment for pain management medications that are driving the market growth.
The companies like Purdue Pharma L.P., Novartis, Daiichi Sankyo, Inc., Egalet Corp., Eli Lilly and Company, Insys Therapeutics, Inc., Cipher Pharmaceuticals Inc., GlaxoSmithKline, Hikma Pharmaceuticals PLC, Johnson & Johnson, Lupin Ltd., Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc. and Acura Pharmaceuticals, Inc. are responsible for growth in the Asia Pacific pain management drugs market.